Imaging Quality in Prostate Cancer: Impact on Treatment Decision-Making
Panelists discuss how high-quality imaging is crucial for accurately staging prostate cancer, guiding treatment decisions, and optimizing patient outcomes. Superior resolution and sensitivity of PSMA PET tracers enhance lesion detection, influencing surgical, radiation, and systemic therapy choices. Differences in tracer properties impact specificity, affecting treatment planning. Advanced imaging reduces uncertainty, improving risk stratification and therapeutic precision.
EP: 1.The Evolving Role of PSMA PET in Prostate Cancer Imaging and Management
EP: 2.PSMA PET Imaging Agents: Image Quality and Diagnostic Performance
EP: 3.Selecting the Optimal PSMA PET Imaging Agent: Clinical Considerations and Data-Driven Decisions
EP: 4.Imaging Quality in Prostate Cancer: Impact on Treatment Decision-Making
EP: 5.PSMA PET Imaging in Prostate Cancer Staging: Guiding Initial Diagnosis and Treatment Decisions
EP: 6.PSMA PET Imaging in Biochemical Recurrence: Clinical Approaches and Data-Driven Decisions
EP: 7.Role of PSMA PET Imaging in Guiding Surgical Treatment Decisions in Prostate Cancer
EP: 8.Leveraging PSMA PET Imaging in Posttreatment Response Assessment: Evolving Practices and Data Insights
EP: 9.Utilizing PSMA PET Imaging in Metastatic Prostate Cancer to Guide Treatment Strategies
EP: 10.Case Discussion: Integrating PSMA PET for Focal Boost Optimization
EP: 11.Evaluating the Role of Cu-PSMA PET Imaging in Prostate Cancer
EP: 12.Key Takeaways and Future Perspectives: PSMA PET Imaging in Prostate Cancer
Video content above is prompted by the following:
- Briefly discuss the importance of imaging quality in guiding treatment decisions for prostate cancer. How do these quality differences impact your clinical decision-making?
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
